Panacea Life Sciences signs LOI to acquire N7 Enterprises for 22.2M shares

PANACEA LIFE SCIENCES HOLDINGS, INC.

Panacea will issue 22.2 million common shares to N7 Enterprises stockholders.
N7 Enterprises had $4.1M revenue in FY2022 and estimated net income exceeding $1M.
Expected close on or around February 28, 2023, subject to due diligence and definitive agreement.
N7 operates Florida kava/kratom lounges (Lizard Juice, N7 Nitro Kava) and a distribution subsidiary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.